|
1
|
Griffiths CE and Barker JN: Pathogenesis
and clinical features of psoriasis. Lancet. 370:263–271.
2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gudjonsson JE and Elder JT: Psoriasis:
Epidemiology. Clin Dermatol. 25:535–546. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ardeleanu V, Sabina Radaschin D and Tatu
AL: Excimer laser for psoriasis treatment: A case report and short
review. Exp Ther Med. 20:52–55. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kruger G, Koo J, Lebwohl M, Menter A,
Stern RS and Rolstad T: The impact of psoriasis on quality of life:
Results of a 1998 national psoriasis foundation patient-membership
survey. Arch Dermatol. 137:280–284. 2001.PubMed/NCBI
|
|
5
|
Menter A, Gottlieb A, Feldman SR, Van
Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA,
Korman NJ, et al: Guidelines of care for the management of
psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis
and guidelines of care for the treatment of psoriasis with
biologics. J Am Acad Dermatol. 58:826–850. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nwabudike LC and Tatu AL: Using
complementary and alternative medicine for the treatment of
psoriasis: A step in the right direction. JAMA Dermatol.
155(636)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Basavaraj KH, Ashok NM, Rashmi R and
Praveen TK: The role of drugs in the induction and/or exacerbation
of psoriasis. Int J Dermatol. 49:1351–1361. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tatu AL, Elisei AM, Chioncel V, Miulescu M
and Nwabudike LC: Immunologic adverse reactions of β-blockers and
the skin. Exp Ther Med. 18:955–959. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li SJ, Perez-Chada LM and Merola JF: TNF
inhibitor-induced psoriasis: Proposed algorithm for treatment and
management. J Psoriasis Psoriatic Arthritis. 4:70–80.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Naldi L: Malignancy concerns with
psoriasis treatments using phototherapy, methotrexate, cyclosporin,
and biologics: Facts and controversies. Clin Dermatol. 28:88–92.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen YJ, Chang YT, Wang CB and Wu CY: The
risk of cancer in patients with rheumatoid arthritis: A nationwide
cohort study in Taiwan. Arthritis Rheum. 63:352–358.
2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Goldacre MJ, Wotton CJ, Yeates D,
Seagroatt V and Jewell D: Cancer in patients with ulcerative
colitis, Crohn's disease and coeliac disease: Record linkage study.
Eur J Gastroenterol Hepatol. 20:297–304. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen YJ, Wu CY, Chen TJ, Shen JL, Chu SY,
Wang CB and Chang YT: The risk of cancer in patients with
psoriasis: A population-based cohort study in Taiwan. J Am Acad
Dermatol. 65:84–91. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
McKenna KE, Patterson CC, Handley J,
McGinn S and Allen G: Cutaneous neoplasia following PUVA therapy
for psoriasis. Br J Dermatol. 134:639–642. 1996.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Murdaca G, Colombo BM, Cagnati P, Gulli R,
Spanò F and Puppo F: Update upon efficacy and safety of TNF-α
inhibitors. Expert Opin Drug Saf. 11:1–5. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Patel RV, Clark LN, Lebwohl M and Weinberg
JM: Treatments for psoriasis and the risk of malignancy. J Am Acad
Dermatol. 60:1001–1017. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Scott FI, Mamtani R, Brensinger CM, Haynes
K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT,
et al: Risk of nonmelanoma skin cancer associated with the use of
immunosuppressant and biologic agents in patients with a history of
autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol.
152:164–172. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nwabudike LC and Tatu AL: Response
to-chronic exposure to tetracyclines and subsequent diagnosis for
non-melanoma skin cancer in a large Mid-Western US population. J
Eur Acad Dermatol Venereol. 32(e159)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mercer LK, Askling J, Raaschou P, Dixon
WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh
A, et al: Risk of invasive melanoma in patients with rheumatoid
arthritis treated with biologics: Results from a collaborative
project of 11 European biologic registers. Ann Rheum Dis.
76:386–391. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sbidian E, Chaimani A, Garcia-Doval I, Do
G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, et
al: Systemic pharmacological treatments for chronic plaque
psoriasis: A network meta-analysis. Cochrane Database Syst Rev.
12(CD011535)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Smith CH, Anstey AV, Barker JN, Burden AD,
Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh
NJ, et al: British association of dermatologists guidelines for use
of biological interventions in psoriasis 2005. Br J Dermatol.
153:486–497. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wong T, Hsu L and Liao W: Phototherapy in
psoriasis: A review of mechanisms of action. J Cutan Med Surg.
17:6–12. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gross RL, Schwartzman-Morris JS, Krathen
M, Reed G, Chang H, Saunders KC, Fisher MC, Greenberg JD, Putterman
C, Mease PJ, et al: A comparison of malignancy incidence among
psoriatic and rheumatoid arthritis patients in a large US cohort.
Arthritis Rheumatol. 66:1472–1481. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non melanoma
skin cancer (Review). Oncol Rep. 38:1327–1340. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Polachek A, Muntyanu A, Lee KA, Ye JY,
Chandran V, Cook RJ and Gladman DD: Malignancy in psoriatic
disease: Results from prospective longitudinal cohorts. Semin
Arthritis Rheum. 51:144–149. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A
and Gelfand JM: The risk of cancer in patients with psoriasis: A
population-based cohort study in the health improvement network.
JAMA Dermatol. 152:282–290. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nwabudike LC and Tatu AL: Reply to
Gambichler T et al. Altered epigenetic pathways and cell
cycle dysregulation in healthy appearing skin of patients with
koebnerized squamous cell carcinomas following skin surgery. J Eur
Acad Dermatol Venereol. 33:e3–e4. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rebegea L, Firescu D, Baciu G and Ciubara
A: Psycho-oncology support. BRAIN Broad Res Artif Intell Neurosci.
10:77–88. 2019.
|
|
29
|
Beyaert R, Beaugerie L, Van Assche G,
Brochez L, Renauld JC, Viguier M, Cocquyt V, Jerusalem G, Machiels
JP, Prenen H, et al: Cancer risk in immune mediated inflammatory
diseases (IMID). Mol Cancer. 12(98)2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pérez Ramírez S, Parra V, Avilés Izquierdo
JA, Vicario JL, Martín M and Márquez-Rodas I: Metastatic melanoma
with spontaneous regression, psoriasis and HLA-Cw6: Case report and
a hypothesis to explore. Tumori. 100:144e–147e. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Niculet E, Bobeica C and Tatu AL:
Glucocorticoid-induced skin atrophy: The old and the new. Clin
Cosmet Investig Dermatol. 13:1041–1050. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sezer E, Özturk Durmaz E, Çetin E and
Şahin S: Meyerson phenomenon as a component of melanoma in situ.
Acta Dermatovenerol Croat. 24:81–82. 2016.PubMed/NCBI
|
|
33
|
Kluger N, Estève E, Fouéré S,
Dupuis-Fourdan F, Jegou MH and Lévy-Rameau C: Tattooing and
psoriasis: A case series and review of the literature. Int J
Dermatol. 56:822–827. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chapman BP and Moynihan J: The brain-skin
connection: Role of psychosocial factors and neuropeptides in
psoriasis. Expert Rev Clin Immunol. 5:623–627. 2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kamata M and Tada Y: Safety of biologics
in psoriasis. J Dermatol. 45:279–286. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cohen BL and Sachar DB: Update on
anti-tumor necrosis factor agents and other new drugs for
inflammatory bowel disease. BMJ. 357(j2505)2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Crusz SM and Balkwill FR: Inflammation and
cancer: Advances and new agents. Nat Rev Clin Oncol. 12:584–596.
2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Neagu M, Constantin C, Tanase C and Boda
D: Patented biomarker panels in early detection of cancer. Recent
Pat Biomark. 1:10–14. 2011.
|
|
39
|
Geller S, Xu H, Lebwohl M, Nardone B,
Lacouture ME and Kheterpal M: Malignancy risk and recurrence with
psoriasis and its treatments: A concise update. Am J Clin Dermatol.
19:363–375. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Papp K, Gottlieb AB, Naldi L, Pariser D,
Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W,
et al: Safety surveillance for ustekinumab and other psoriasis
treatments from the psoriasis longitudinal assessment and registry
(PSOLAR). J Drugs Dermatol. 14:706–714. 2015.PubMed/NCBI
|
|
41
|
Karram S, Novy M, Saroufim M, Loya A,
Taraif S, Houreih MA, Rauscher B, Habib RH, Oberkanins C and
Khalifeh I: Predictors of BRAF mutation in melanocytic nevi:
Analysis across regions with different UV radiation exposure. Am J
Dermatopathol. 35:412–418. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ferringer T: Update on
immunohistochemistry in melanocytic lesions. Dermatol Clin.
30:567–579, v. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Clark WH Jr, Elder DE, Guerry D IV,
Epstein MN, Greene MH and Van Horn M: A study of tumor progression:
The precursor lesions of superficial spreading and nodular
melanoma. Hum Pathol. 15:1147–1165. 1984.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Silva JH, Sá BC, Avila AL, Landman G and
Duprat Neto JP: Atypical mole syndrome and dysplastic nevi:
Identification of populations at risk for developing
melanoma-review article. Clinics (Sao Paulo). 66:493–499.
2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Marinescu SA, Tatu AL, Mihai IR and
Giuglea C: Correlations between clinics, dermoscopy and
histopathology in a female with two dermatofibromas-a case report.
Rom J Morphol Embryol. 57:323–326. 2016.PubMed/NCBI
|
|
46
|
Kittler H: Use of digital dermoscopy to
monitor melanocytic lesions: Risks and benefits. J Drugs Dermatol.
2:309–311. 2003.PubMed/NCBI
|
|
47
|
Tatu AL: Umbilicated blue-black lesion on
the lateral thorax. J Cutan Med Surg. 21(252)2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Marghoob AA and Scope A: The complexity of
diagnosing melanoma. J Invest Dermatol. 129:11–13. 2009.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Passarelli A, Mannavola F, Stucci LS,
Tucci M and Silvestris F: Immune system and melanoma biology: A
balance between immunosurveillance and immune escape. Oncotarget.
8:106132–106142. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Bastian BC: The molecular pathology of
melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev
Pathol. 9:239–271. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Stefan O, Tudor G, Constantinescu C, Luca
C, Boda D, Caruntu C, Cioplea M, Nichita L and Zurac SA: E-cadherin
and N-cadherin expression pattern in common melanocytic nevi.
Virchows Arch. 475(S28)2019.
|
|
52
|
Di Cesare A, Riitano A, Suppa M, Fidanza
R, Zangrilli A, Esposito M, Fargnoli MC, Chimenti S and Peris K:
Frequency of melanocytic nevi in psoriatic patients is related to
treatment and not to disease severity. J Am Acad Dermatol.
69:947–953. 2013.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Cengiz FP, Emiroglu N, Bahali AG, Ozkaya
DB, Su O and Onsun N: The relationship of psoriasis and melanocytic
nevi. Indian J Dermatol. 61:664–667. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Balato N, Di Costanzo L, Balato A, Patruno
C, Scalvenzi M and Ayala F: Psoriasis and melanocytic naevi: Does
the first confer a protective role against melanocyte progression
to naevi? Br J Dermatol. 164:1262–1270. 2011.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Katoulis AC, Kanelleas A, Zambacos G,
Panayiotides I and Stavrianeas NG: Development of two primary
malignant melanomas after treatment with adalimumab: A case report
and review of the possible link between biological therapy with
TNF-alpha antagonists and melanocytic proliferation. Dermatology.
221:9–12. 2010.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Queirós CS, Laureano-Oliveira A,
Lopéz-Presa D and Filipe P: Spitz nevus and infliximab: Association
or coincidence? An Bras Dermatol. 95:615–618. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Manganoni AM, Zane C, Pavoni L, Farisoglio
C, Sereni E and Calzavara-Pinton P: Cutaneous melanoma in patients
in treatment with biological therapy: Review of the literature and
case report. Dermatol Online J. 17(12)2011.PubMed/NCBI
|
|
58
|
Zurac S, Neagu M, Constantin C, Cioplea M,
Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et
al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in
cutaneous melanoma with regression and their possible function as
prognostic predictors. Oncol Lett. 11:3354–3360. 2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Johnson DB, Sullivan RJ, Ott PA, Carlino
MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP,
Buchbinder EI, et al: Ipilimumab therapy in patients with advanced
melanoma and preexisting autoimmune disorders. JAMA Oncol.
2:234–240. 2016.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Nadesalingam K, Goodfield M and Emery P:
Halo naevi, vitiligo and diffuse alopecia areata associated with
tocilizumab therapy. Oxf Med Case Reports.
2016(omw027)2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Niculet E, Chioncel V, Elisei AM, Miulescu
M, Buzia OD, Nwabudike LC, Craescu M, Draganescu M, Bujoreanu F,
Marinescu E, Marinescu E, et al: Multifactorial expression of IL-6
with update on COVID-19 and the therapeutic strategies of its
blockade (review). Exp Ther Med. 21(263)2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Koseoglu G, Akay BN, Kucuksahin O and
Erdem C: Dermoscopic changes in melanocytic nevi in patients
receiving immunosuppressive and biologic treatments: Results of a
prospective case-control study. J Am Acad Dermatol. 73:623–629.
2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Giurcaneanu C, Nitipir C, Popa LG, Forsea
AM, Popescu I and Bumbacea RS: Evolution of melanocytic nevi under
vemurafenib, followed by combination therapy with dabrafenib and
trametinib for metastatic melanoma. Acta Dermatovenerol Croat.
23:114–121. 2015.PubMed/NCBI
|
